E-Acadêmica
October 10, 2022
Roberto Carlos Moreira Kuligowski, Eduarda Maria Schroeder, João Vitor Pelizzari et al.
Introduction: Studies about alternative medicine have multiplied in several countries such as the United States, Norway and England in recent years. Among them, I highlight psychedelic medicine that through randomized clinical trials, has already shown that psilocybin - substance present in the Psilocybe cubensis mushroom, popularly known as "magic mushrooms" - was able to induce remission of...
Applied Psychology: Health and Well-Being
October 10, 2022
Constance Karing
31 citations
The increasing mental health issues among university students during the COVID-19 pandemic and the challenges of delivering face-to-face interventions during lockdowns have increased the demand for online interventions. The report presents results from a randomized controlled trial investigating the benefits of online mindfulness interventions delivered by videoconference or podcast during the...
BMJ
October 6, 2022
Joanne Silberner
1 citation
As a flurry of US states approve psilocybin for medicinal use, Joanne Silberner asks whether the most carefully studied of psychedelic drugs will revolutionise treatment of depression and other psychiatric ailments
European Journal of Investigation in Health, Psychology and Education
October 5, 2022
Roberto Chiodelli, Saul Neves de Jesús, Luana Thereza Nesi de Mello et al.
10 citations
Rates of mental health issues have been increasing among university students. This study investigates the effects of the Interculturality and Mindfulness Program (PIM) on academic students on mindfulness, emotional regulation, depression, anxiety, stress, life satisfaction, optimism, positive solitude, and loneliness. A quasi-experimental research was conducted, with pre- and post-test...
International Journal of Environmental Research and Public Health
October 5, 2022
Ashley Vroegindewey, Bushra Sabri
Immigrant women are disproportionately affected by intimate partner violence (IPV), which poses risk for mental health problems, such as PTSD and depression. Post-migration barriers limit immigrant women's access to supportive services, which can further debilitate their mental health symptoms and their safety. The Being safe, Healthy, and Positively Empowered (BSHAPE) digital intervention was...
Revista Innova Educación
October 5, 2022
Lee Fergusson, Javier Ortíz, Anna Bonshek
4 citations
Most of the literature that has emerged about the impacts of home isolation during the COVID-19 pandemic suggests it causes mildly to acutely adverse psychosocial and physiological responses, particularly in children. Such responses relate to the separation children experience from their normal routine, including loneliness, anxiety, and depression, and adversities associated with school...
Frontiers in Psychiatry
October 3, 2022
Jordi Camarasa, Pol Puigseslloses, Edurne Urquizu et al.
5 citations
The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of efficacy, delayed onset of action or side effects. Psychoactive substances have a long history of being used as tools to alter consciousness and as a gateway to approach the unknown and the divinities. These substances were initially obtained from plants...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
October 1, 2022
Francisco de Borja Belloch, M. Cortés-Erice, E. Herzog et al.
The NMDA antagonist ketamine demonstrated a fast antidepressant activity in treatment-resistant depression. Pre-clinical studies suggest that de novo synthesis of the brain-derived neurotrophic factor (BDNF) in the PFC might be involved in the rapid antidepressant action of ketamine. Applying a genetic model of impaired glutamate release, this study aims to further identify the molecular...
Genetic Engineering & Biotechnology News
October 1, 2022
K. Liszewski
A new model of psilocybin therapy is being developed by Compass Pathways, a mental health company. This model involves the administration of a synthetic psilocybin in conjunction with psychological support in order to treat conditions such as treatment-resistant depression. Most recently, Compass announced the launch of a Phase II trial to investigate the efficacy of its synthetic psilocybin...
Neuropharmacology
October 1, 2022
Atsushi Suzuki, Hiroe Hara, H. Kimura
Ketamine exerts rapid and long-lasting antidepressant effects in patients with treatment-resistant depression. However, its clinical use is limited by its undesirable psychotomimetic side effects. Accumulating evidence from preclinical studies has shown that the antidepressant effects of ketamine are dependent on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) activation,...